Soligenix SNGX
NASDAQ SNGX
$0.40 +0.02 (+5.50%)
At close: Aug 21, 2026 · 4:00 PM EDT

Soligenix (SNGX) Change in Accured Expenses (2010 - 2026)

Soligenix's (SNGX) quarterly Change in Accured Expenses came in at $322307.0 in Q1 2026, up 212.73% YoY from $103061.7 in Q1 2025, and down 22.39% on a QoQ basis from $415306.0 in Q4 2025.

Soligenix (SNGX) Change in Accured Expenses (2010 - 2026) Analysis & Trends

Soligenix (SNGX) has 17 years of Change in Accured Expenses data on file, last reported at $322307.0 in Q1 2026.

  • Quarterly Change in Accured Expenses rose 212.73% year-over-year to $322307.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $759895.0 (up 164.92% YoY) and the FY2025 annual result came in at $151683.0, up 130.79% from the prior year.
  • Change in Accured Expenses fell to $322307.0 in Q1 2026, from $415306.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.3 million in Q3 2023 to a low of -$970757.0 in Q1 2023.
  • A 5-year average of $17203.0 and a median of $19712.0 in 2022 frame the typical range for Change in Accured Expenses.
  • Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 4030.29% — and 2023, when it tumbled 3314.57%.
  • Tracing SNGX's Change in Accured Expenses over 5 years: stood at -$282617.0 in 2022, then surged by 169.2% to $195572.0 in 2023, then plunged by 266.62% to -$325860.0 in 2024, then jumped by 227.45% to $415306.0 in 2025, then declined by 22.39% to $322307.0 in 2026.
  • The last three Change in Accured Expenses figures came in at $322307.0 (Q1 2026), $415306.0 (Q4 2025), and -$14370.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 222.50 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 492.70 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 11.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 212.44 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 61.62 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 68.82 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Soligenix 6.45 Mn 6.45 Mn - 861,228.00

Historic Data

Download Data
DateValue
Jun 30, 2026 861,228.00
Jun 30, 2026 861,228.00
Mar 31, 2026 322,307.00
Mar 31, 2026 322,307.00
Dec 31, 2025 415,306.00
Dec 31, 2025 415,306.00
Sep 30, 2025 -14,370.00
Sep 30, 2025 -14,370.00
Jun 30, 2025 36,652.00
Jun 30, 2025 36,652.00
Mar 31, 2025 -285,905.00
Mar 31, 2025 -285,905.00
Dec 31, 2024 -325,860.00
Dec 31, 2024 -325,860.00
Sep 30, 2024 64,336.00
Sep 30, 2024 64,336.00
Jun 30, 2024 -623,018.00
Jun 30, 2024 -623,018.00
Mar 31, 2024 391,929.00
Mar 31, 2024 391,929.00